DRNA News and Press, Dicerna Pharmaceuticals Inc. From 02/11/21

– PHYOX4 Data Expected Mid-Year 2021 – – Planned Nedosiran New Drug Application (NDA) Submission On Track for Third Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”)...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, w...

Dicerna Pharmaceuticals (DRNA) +4% in premarket as its collaborating partner Novo Nordisk (NVO) has nominated its first candidate under the existing agreement, for the discovery and development of therapies for the treatment of liver-related cardiometabolic diseases using Dicerna&#x...

– First Development Candidate Selected Under Multi-Target Collaboration Will Be Evaluated for Treatment of Cardiometabolic Diseases and Triggers $2.5 Million Milestone to Dicerna – – Dicerna Also Earned $25 Million Annual Fee for Delivery of Multiple G...

Dicerna Pharmaceuticals ([[DRNA]] +1.2%) has completed enrollment in PHYOX2 Phase 2 trial evaluating its lead investigational therapy, nedosiran, as a once-monthly treatment of all three known types of primary hyperoxaluria, a rare disorder that mainly affects the kidneys and result...

– Dicerna Expects Trial Completion in First Half of 2021, With Top-Line Data Available Mid-Year – – Enrollment in PHYOX4 Trial for PH3 Expected to Begin in January 2021 – – Planned New Drug Application Submission On Track for Third Qu...

Dicerna is right behind Alnylam in the RNAi space. Its lead candidate is nedosiran targeting primary hyperoxaluria. This is a solid candidate, looking to accumulate at better prices. For further details see: Dicerna: Great Value RNAi Runner Up

Dicerna Pharmaceuticals ([[DRNA]] -2.8%) has announced additional data from Phase 1 trial evaluating GalXC RNAi therapeutic RG6346, under development in collaboration with Roche for the treatment of chronic hepatitis B virus ((HBV)) infection. Data will be presented at the...

FDA has signed-off investigational new drug application ((IND)) filed by Eli Lilly ([[LLY]] +0.3%) for LY3561774, the first candidate to emerge from licensing collaboration between Dicerna ([[DRNA]] -3.8%), and Eli Lilly.The event has triggered a milestone payment of $10M from Eli Lilly,...